Ibuprofen EchoG
Phase 3Small molecule
Ibuprofen EchoG is one of 8 small molecule programs targeting Patent ductus arteriosus. It is currently in Phase 3.
1
Indications
1
Total Trials
0
Active Trials
7
Competitors
Pipeline
Status by Indication[3][1]
Indication
Competition
Competitive Landscape
13 competitors in Patent Ductus Arteriosus
#DrugCompanyPhaseTrials
1Advil
KKenvue Brands
Approved
Indocin
LLife Extension Foundation Inc.
Approved
Caverject
VViatris Specialty LLC
Approved
Paracetamol
GSKPhase 2
Trental
VValidus Pharmaceuticals
Phase 2
Tylenol
KKenvue Brands
Phase 1
D5W
TThe University of Texas Health Science Center at San Antonio
Phase 2
Ibuprofen EchoG
FFundacion para la Investigacion Biomedica del Hospital Universitario la Paz
Phase 3
Ranked by pipeline maturity and clinical activity. Current drug highlighted in teal.
Clinical
Trials by Indication[1]
Patent ductus arteriosus1 trial
Echocardiographically Guided Versus Standard Ibuprofen Treatment for Patent Ductus Arteriosus
Completed·FFundacion para la Investigacion Biomedica del Hospital Universitario la Paz·Phase 3·NCT01593163·49 enrolled
Sources
References
- [1]
- [2]
- [3]Open Targets Platform — Drug–disease associations for Ibuprofen EchoG. EMBL-EBI & Wellcome Sanger Institute.
- [4]
Details